SCHEMBL1103453

SCHEMBL1103453

c1ccc2c(-c3c4ccccc4c(-c4ccc5cc(-c6c7ccccc7c(-c7cccc8ccccc78)c7c6cnc6ccccc67)ccc5c4)c4cnc5ccccc5c34)cccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.42
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
RECQL P46063 1/20 0.38
RAB9A P51151 1/20 0.38
KDM4E B2RXH2 2/20 0.38
GPR3 P46089 1/20 0.38
PIM1 P11309 1/20 0.38
PDGFRB P09619 1/20 0.36
PDGFRA P16234 1/20 0.36
ESR1 P03372 2/20 0.36
ESR2 Q92731 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103575 0.97 MET (0.46) METMAPTSMN1; SMN2NPC1LMNA
SCHEMBL1103580 0.97 MET (0.43) METMAPTSMN1; SMN2NPC1LMNA
SCHEMBL1103566 0.95 MET (0.42) METMAPTSMN1; SMN2NPC1LMNA
SCHEMBL1103457 0.95 ESR1 (0.42) METMAPTSMN1; SMN2NPC1LMNA
SCHEMBL1103579 0.95 MAPT (0.41) METMAPTSMN1; SMN2NPC1LMNA
SCHEMBL1103581 0.94 MET (0.42) METMAPTSMN1; SMN2NPC1LMNA
SCHEMBL1103499 0.94 MET (0.44) METMAPTSMN1; SMN2NPC1LMNA
SCHEMBL1103367 0.94 MET (0.46) METMAPTSMN1; SMN2NPC1LMNA
SCHEMBL1103526 0.92 MET (0.48) METMAPTSMN1; SMN2NPC1LMNA
SCHEMBL1103504 0.91 MET (0.45) METMAPTSMN1; SMN2NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 MET 4191/4885MAPT 3162/4885SMN1; SMN2 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.